"Isn't that the horse tranquilizer?"
That is the sentence. It comes out in kitchens in south county, in break rooms off I-70, in the passenger seat on I-64 when a sister finally says the quiet part about her brother. Nobody is being rude. They are protecting someone they love.
So take it seriously. Veterinarians do use ketamine. So do operating rooms and emergency departments, where it has been a human anesthetic for decades. The question goes sideways at the assumption that the clinic version for depression resembles the one in the rumor.
To learn what people around here believe, we funded a poll of 443 adults across the Midwest. Respondents leaning open came to 51 percent, and only 9 percent were firmly against. The room is not hostile; it is uninformed, and it knows it. Six beliefs come up most.
Belief one: it is just the party drug, so it cannot be real medicine
How a substance is misused tells you almost nothing about how it works under supervision. Dose, setting, and monitoring are the whole difference: in a clinic the dose is measured to you, a clinician is present, and your vitals are watched. So separate the substance from the setting and ask the practical question, which is who gives it, where, and with what oversight.
Belief two: none of this is FDA-approved
Part of it is approved and part is not, and that difference matters more than almost anything else here.
- Esketamine, the drug inside Spravato, is a nasal spray approved by federal regulators for depression that standard medicines have not relieved. It is dosed only inside certified offices, followed by a monitoring period, and no version of it goes home in your bag.
- Generic ketamine infused for depression is off label: a licensed clinician may prescribe it on medical judgment, but that use has not been through FDA approval. Legal and common is not the same as approved.
- At-home ketamine ordered through a website is a third category and the least regulated.
Our respondents care about that line. For 59 percent, FDA approval would settle the question or weigh on it heavily, and 27 percent named it among their two biggest provider criteria. So ask, in those words, which one is on offer. A straight answer is a good sign; a pivot to testimonials is not.
Belief three: it is cash-only, for people with money
The payer picture in our sample looks nothing like the boutique stereotype. Commercial coverage topped the list at 39 percent with Medicaid a step behind at 37; TRICARE (5), Medicare (23), and no insurance (9) trailed, and people could choose more than one.
Coverage was also the loudest signal. Insurance was a first- or second-ranked provider criterion for 85 percent, and for 65 percent it would be decisive or close to it. Given insurance with more hoops or paying and starting sooner, 51 percent took the hoops. Paying appealed to 23 percent; the remaining 26 percent were torn.
If coverage is your gate, say so on the first call and ask what they accept, including Missouri Medicaid, which you may know as MO HealthNet. For one example of how a certified program explains its visits, see Brain Recovery Centers' Spravato treatment page, then confirm billing with whichever clinic you call.
Belief four: you can do it at home, so the clinic version is a markup
They are not the same product at different prices. The approved spray is never dispensed for home use. You take it in a certified setting, stay for monitoring, and do not drive yourself home that day.
Those requirements are the treatment, not an upsell. The dosing window affects blood pressure, perception, and alertness, and someone qualified should be in the building while it passes.
Belief five: if it were any good, my doctor would have offered it already
This is the most understandable belief here and the one most likely to cost someone a year. Public awareness is very low. In our survey, Spravato was unknown to 73 percent. It was a bare name to 21 percent, and something only 6 percent could actually explain.
That describes the public, not physicians, so it says nothing about what any doctor knows. It does say almost nobody walks into an appointment able to name this, and a topic neither side raises never comes up. Meanwhile, the people we asked put their own doctor's advice far ahead of anything else as a reason to try it, at 74 percent; ads got 2 percent.
So raise it yourself: "I read that esketamine is used when antidepressants have not worked. Should I be evaluated for that, or is there something better for me?" A no from someone who knows your history beats a yes from the internet.
Belief six: being open to it means being desperate or reckless
Openness here is ordinary. When our survey asked how people first felt about ketamine as depression or PTSD care, cautious but open ran far in front at 34 percent. Skeptics made up 21 percent. Hopeful or curious respondents and those new to the idea each came to 18 percent, and negative trailed at 9.
There is a reason. Asked about their own lives, 72 percent described depression, anxiety, or PTSD that would not yield to routine medicine, in their own life or a loved one's. Thirty-seven percent meant themselves, 22 percent a person close by, and 13 percent both, while 28 percent said neither.
Curiosity after standard treatment has failed is not desperation. It is what people do when the first answer did not work and they still have a life to get back to.
What none of this can tell you
This is market research about beliefs, not clinical evidence, and it offers no medical advice and no forecast of anyone's outcome. Whether ketamine or esketamine fits you is a clinician's judgment, and some people should not have it at all.
One thing outranks everything above. If the weight has gotten heavy enough that you have thought about not being here, do not wait for an appointment. Text or dial 988 and a trained Lifeline counselor picks up, day or night, and you can reach out about someone else, too.
Methodology
This survey was ours: we commissioned it and paid for it. Pollfish fielded it on its consumer panel. By the June 23, 2026 close, responses had come in from 443 people between 18 and 64 in Missouri, Illinois, Iowa, Kansas, and six other Midwest states. Multi-select shares can sum past 100. Everything reflects the validated panel.